LGM

Logos Global Management Portfolio holdings

AUM $1.01B
1-Year Est. Return 90.41%
This Quarter Est. Return
1 Year Est. Return
+90.41%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$1.01B
AUM Growth
+$264M
Cap. Flow
Cap. Flow %
Top 10 Hldgs %
Holding
71
New
Increased
Reduced
Closed

Top Buys

1
+$35.2M
2
+$26.9M
3
+$22.5M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$19.9M
5
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$19.7M

Top Sells

1
+$33M
2
+$29.8M
3
+$24.4M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$18.9M
5
KROS icon
Keros Therapeutics
KROS
+$18.2M

Sector Composition

1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MREO
51
Mereo BioPharma
MREO
$293M
$1.03M 0.09%
+500,000
GUTS icon
52
Fractyl Health
GUTS
$214M
$795K 0.07%
+500,000
NUVB.WS icon
53
Nuvation Bio Inc Warrants
NUVB.WS
$73.1M
$13.5K ﹤0.01%
66,666
ALEC icon
54
Alector
ALEC
$134M
– –
0
ANNX icon
55
Annexon
ANNX
$616M
– –
-2,410,000
APLS icon
56
Apellis Pharmaceuticals
APLS
$2.68B
– –
0
BHVN icon
57
Biohaven
BHVN
$1.24B
– –
-700,000
CLDX icon
58
Celldex Therapeutics
CLDX
$1.72B
– –
-600,000
KRYS icon
59
Krystal Biotech
KRYS
$6.24B
– –
-100,000
LEGN icon
60
Legend Biotech
LEGN
$4.96B
– –
-250,000
LRMR icon
61
Larimar Therapeutics
LRMR
$304M
– –
0
MDGL icon
62
Madrigal Pharmaceuticals
MDGL
$13.2B
– –
-50,000
MLTX icon
63
MoonLake Immunotherapeutics
MLTX
$939M
– –
-200,000
NBIX icon
64
Neurocrine Biosciences
NBIX
$15B
– –
-150,000
TEVA icon
65
Teva Pharmaceuticals
TEVA
$30.7B
– –
0
UTHR icon
66
United Therapeutics
UTHR
$20.7B
– –
-85,000
XBI icon
67
State Street SPDR S&P Biotech ETF
XBI
$7.95B
– –
0
XNCR icon
68
Xencor
XNCR
$1.18B
– –
-1,250,000
RAPP
69
Rapport Therapeutics
RAPP
$1.36B
– –
-208,910
BCAX
70
Bicara Therapeutics
BCAX
$949M
– –
-400,000
MTSR
71
DELISTED
Metsera Inc
MTSR
– –
-200,000
1 2
3